BR112018002550A2 - inhibitor resistance mechanism - Google Patents
inhibitor resistance mechanismInfo
- Publication number
- BR112018002550A2 BR112018002550A2 BR112018002550-0A BR112018002550A BR112018002550A2 BR 112018002550 A2 BR112018002550 A2 BR 112018002550A2 BR 112018002550 A BR112018002550 A BR 112018002550A BR 112018002550 A2 BR112018002550 A2 BR 112018002550A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- bet
- cancer
- brd4
- bcl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/04—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562203128P | 2015-08-10 | 2015-08-10 | |
| US62/203,128 | 2015-08-10 | ||
| PCT/US2016/046318 WO2017027571A1 (en) | 2015-08-10 | 2016-08-10 | Mechanism of resistance to bet bromodomain inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018002550A2 true BR112018002550A2 (en) | 2018-09-18 |
Family
ID=57984534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018002550-0A BR112018002550A2 (en) | 2015-08-10 | 2016-08-10 | inhibitor resistance mechanism |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11666580B2 (enExample) |
| EP (2) | EP4585273A3 (enExample) |
| JP (1) | JP2018531891A (enExample) |
| KR (1) | KR20180035905A (enExample) |
| CN (1) | CN108137550A (enExample) |
| AU (2) | AU2016304856B8 (enExample) |
| BR (1) | BR112018002550A2 (enExample) |
| CA (1) | CA2995374A1 (enExample) |
| CL (1) | CL2018000377A1 (enExample) |
| HK (1) | HK1254201A1 (enExample) |
| IL (1) | IL257386A (enExample) |
| MX (1) | MX2018001737A (enExample) |
| PE (1) | PE20181088A1 (enExample) |
| RU (1) | RU2018108165A (enExample) |
| WO (1) | WO2017027571A1 (enExample) |
| ZA (1) | ZA201800969B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180035905A (ko) | 2015-08-10 | 2018-04-06 | 다나-파버 캔서 인스티튜트 인크. | Bet 브로모도메인 억제제에 대한 저항성의 메카니즘 |
| GB201704536D0 (en) * | 2017-03-22 | 2017-05-03 | Univ Malta | Method |
| US11712439B2 (en) | 2017-08-09 | 2023-08-01 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating bet inhibitor-resistant cancers |
| CN109503618A (zh) * | 2017-09-14 | 2019-03-22 | 成都海创药业有限公司 | 一种brd4抑制剂 |
| CN108084193A (zh) * | 2017-12-19 | 2018-05-29 | 郭守东 | 一种brd4蛋白抑制剂 |
| WO2020023768A1 (en) | 2018-07-25 | 2020-01-30 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating bet inhibitor-resistant cancers |
| US20220062291A1 (en) * | 2018-12-21 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a) with reduced inhibitory activity targeted to the dopamine d2 receptor and accompanying toxicity |
| PT116050B (pt) * | 2020-01-09 | 2022-06-15 | Hovione Farm S A | Conjugados fármaco-ligando e inibidores das proteínas da família bromodomínio e domínio extraterminal -(bet) modificados |
| AU2021298154A1 (en) * | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| WO2023041744A1 (en) | 2021-09-17 | 2023-03-23 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
| EP4480494A4 (en) * | 2022-02-16 | 2026-03-11 | Univ Nat Corp Tokyo Medical & Dental | COMPOSITION INTENDED FOR USE IN THE TREATMENT OF CANCER, INFLAMMATORY DISEASES OR OBESITY, AND ITS USE |
| CN114617878A (zh) * | 2022-05-16 | 2022-06-14 | 深圳大学 | Ck2抑制剂在制备抗衰药物中的应用 |
| CN115894678B (zh) * | 2022-07-15 | 2023-10-20 | 新疆赛尔托马斯生物科技有限公司 | 一种干细胞细胞因子的制备方法及其在制备药品中的用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA103867A (en) | 1907-02-01 | 1907-03-05 | Charles M. Thrasher | Nut lock |
| CA120184A (en) | 1908-09-08 | 1909-08-24 | George Albert Thornhill | Bottle labelling machine |
| CA168504A (en) | 1915-01-09 | 1916-03-28 | Carl Lorentz Nilson | Locomotive |
| AU6854098A (en) | 1997-04-18 | 1998-11-13 | Chugai Research Institute For Molecular Medicine, Inc. | Transcriptional regulator |
| EP1077219A4 (en) | 1998-04-30 | 2005-02-23 | Chugai Pharmaceutical Co Ltd | Transcriptional, regulatory factor |
| US20120028912A1 (en) | 2000-02-22 | 2012-02-02 | J.David Gladstone Institute | Methods of modulating bromodomains |
| US6607916B2 (en) | 2001-02-08 | 2003-08-19 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Casein kinase 2-alpha expression |
| US8522267B2 (en) | 2002-03-08 | 2013-08-27 | Caption Colorado Llc | Method and apparatus for control of closed captioning |
| US8557812B2 (en) | 2004-08-20 | 2013-10-15 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof |
| WO2006065724A2 (en) | 2004-12-14 | 2006-06-22 | Regents Of The University Of Minnesota | Casein kinase 2 antisense therapy |
| WO2006069186A2 (en) | 2004-12-22 | 2006-06-29 | The Ohio State Research Foundation | Small molecule bcl-xl/bcl-2 binding inhibitors |
| WO2008060695A2 (en) | 2006-05-22 | 2008-05-22 | The Trustees Of The University Of Pennsylvania | Antiviral inhibition of casein kinase ii |
| WO2007143081A2 (en) | 2006-06-02 | 2007-12-13 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of lymphoid malignancies |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| WO2008119109A1 (en) | 2007-03-29 | 2008-10-09 | Velacor Therapeutics Pty Ltd | Treatment of neurological disorders |
| ES2529790T3 (es) | 2007-04-13 | 2015-02-25 | Dana-Farber Cancer Institute, Inc. | Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB |
| US8476260B2 (en) | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
| WO2009117769A1 (en) * | 2008-03-25 | 2009-10-01 | Newcastle Innovation Limited | Inhibition of c-kit cancers |
| JP2012523458A (ja) | 2009-04-13 | 2012-10-04 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | タンパク質ホスファターゼ２ａ活性化剤 |
| US9307184B2 (en) | 2009-07-31 | 2016-04-05 | Echostar Technologies L.L.C. | Multi-user recording allocation |
| US8865901B2 (en) | 2009-10-02 | 2014-10-21 | Fred Hutchinson Cancer Research Center | Gain-of-function Bcl-2 inhibitors |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| US9360482B2 (en) | 2009-11-05 | 2016-06-07 | Glaxosmithkline Llc | Process for the identification of a compound which inhibits the binding of the second bromodomain of each of human BRD-2, BRD-3, and BRD-4 |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| US8862173B2 (en) | 2009-12-10 | 2014-10-14 | Motorola Solutions, Inc. | Method for selecting media for delivery to users at an incident |
| US20110207789A1 (en) | 2010-02-19 | 2011-08-25 | Ye Fang | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
| MX373121B (es) | 2010-05-14 | 2020-04-30 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| MX384074B (es) | 2010-05-14 | 2025-03-12 | Dana Farber Cancer Inst Inc | Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| MY165884A (en) | 2010-11-23 | 2018-05-18 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
| US9249161B2 (en) * | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| JP5998152B2 (ja) | 2011-01-25 | 2016-09-28 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Ｂｃｌ−２／ｂｃｌ−ｘｌ阻害剤およびそれを使用する治療方法 |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US9220706B2 (en) | 2012-06-01 | 2015-12-29 | National Institutes Of Health (Nih) | Inhibition of leukemic stem cells by PP2A activating agents |
| EP2861255B1 (en) * | 2012-06-19 | 2019-10-09 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
| DE102012212436B4 (de) | 2012-07-16 | 2022-07-14 | Coretronic Corporation | Lichtmodul für eine Projektionsvorrichtung und Verfahren zur Generierung des Blauanteils in einem Lichtmodul für eine Projektionsvorrichtung |
| WO2014039994A2 (en) | 2012-09-07 | 2014-03-13 | Carlos Cordon-Cardo | Targeting chemotherapy agent resistance in cancer |
| US20140296218A1 (en) * | 2012-10-25 | 2014-10-02 | Whitehead Institute For Biomedical Research | Super-enhancers and methods of use thereof |
| US9073878B2 (en) * | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| WO2015018522A1 (en) | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| EP3066101B1 (en) * | 2013-11-08 | 2020-07-29 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| CN105960239A (zh) | 2013-11-27 | 2016-09-21 | 翁科埃斯克斯有限公司 | 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法 |
| WO2015109286A1 (en) * | 2014-01-20 | 2015-07-23 | Gilead Sciences, Inc. | Therapies for treating cancers |
| WO2016203335A1 (en) * | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| KR20180035905A (ko) | 2015-08-10 | 2018-04-06 | 다나-파버 캔서 인스티튜트 인크. | Bet 브로모도메인 억제제에 대한 저항성의 메카니즘 |
-
2016
- 2016-08-10 KR KR1020187006573A patent/KR20180035905A/ko not_active Withdrawn
- 2016-08-10 US US15/751,914 patent/US11666580B2/en active Active
- 2016-08-10 WO PCT/US2016/046318 patent/WO2017027571A1/en not_active Ceased
- 2016-08-10 AU AU2016304856A patent/AU2016304856B8/en active Active
- 2016-08-10 BR BR112018002550-0A patent/BR112018002550A2/en not_active IP Right Cessation
- 2016-08-10 HK HK18113341.9A patent/HK1254201A1/zh unknown
- 2016-08-10 EP EP25171764.1A patent/EP4585273A3/en active Pending
- 2016-08-10 CA CA2995374A patent/CA2995374A1/en not_active Abandoned
- 2016-08-10 CN CN201680058347.9A patent/CN108137550A/zh active Pending
- 2016-08-10 EP EP16835823.2A patent/EP3334725B1/en active Active
- 2016-08-10 JP JP2018506976A patent/JP2018531891A/ja active Pending
- 2016-08-10 RU RU2018108165A patent/RU2018108165A/ru unknown
- 2016-08-10 MX MX2018001737A patent/MX2018001737A/es unknown
- 2016-08-10 PE PE2018000226A patent/PE20181088A1/es unknown
-
2018
- 2018-02-07 IL IL257386A patent/IL257386A/en unknown
- 2018-02-09 CL CL2018000377A patent/CL2018000377A1/es unknown
- 2018-02-13 ZA ZA2018/00969A patent/ZA201800969B/en unknown
-
2021
- 2021-04-20 AU AU2021202388A patent/AU2021202388A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016304856B2 (en) | 2021-01-21 |
| CA2995374A1 (en) | 2017-02-16 |
| HK1254201A1 (zh) | 2019-07-12 |
| US11666580B2 (en) | 2023-06-06 |
| EP3334725A4 (en) | 2019-07-31 |
| EP4585273A3 (en) | 2025-10-22 |
| RU2018108165A (ru) | 2019-09-12 |
| MX2018001737A (es) | 2018-09-06 |
| IL257386A (en) | 2018-04-30 |
| JP2018531891A (ja) | 2018-11-01 |
| AU2021202388A1 (en) | 2021-05-20 |
| KR20180035905A (ko) | 2018-04-06 |
| ZA201800969B (en) | 2020-10-28 |
| AU2016304856A1 (en) | 2018-03-01 |
| EP4585273A2 (en) | 2025-07-16 |
| AU2016304856B8 (en) | 2021-02-18 |
| WO2017027571A8 (en) | 2017-04-20 |
| EP3334725B1 (en) | 2025-04-23 |
| EP3334725A1 (en) | 2018-06-20 |
| RU2018108165A3 (enExample) | 2019-12-25 |
| US20200368248A1 (en) | 2020-11-26 |
| CN108137550A (zh) | 2018-06-08 |
| PE20181088A1 (es) | 2018-07-09 |
| AU2016304856A8 (en) | 2021-02-18 |
| WO2017027571A1 (en) | 2017-02-16 |
| CL2018000377A1 (es) | 2018-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3334725B1 (en) | Bromodomain and extra terminal (bet) inhibitor and a protein phosphatase 2a (pp2a) activator for treating bet inhibitor resistant cancer | |
| JP7323592B2 (ja) | 癌を治療するための併用療法 | |
| Nabissi et al. | Cannabidiol stimulates A ml‐1a‐dependent glial differentiation and inhibits glioma stem‐like cells proliferation by inducing autophagy in a TRPV 2‐dependent manner | |
| EP2861255B1 (en) | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy | |
| ES3055185T3 (en) | Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator | |
| CA2953079C (en) | Intermittent dosing of mdm2 inhibitor | |
| AU2014246667A1 (en) | Methods of treating diseases characterized by excessive Wnt signalling | |
| CN113164779A (zh) | 治疗cdk4/6抑制剂耐药性癌症的方法 | |
| Mologni et al. | Colorectal tumors are effectively eradicated by combined inhibition of β-catenin, KRAS, and the oncogenic transcription factor ITF2 | |
| WO2008078109A2 (en) | Medicament | |
| CA2890108C (en) | Method for treating prostate cancer | |
| JP2023507816A (ja) | がんを治療するための方法及び組成物 | |
| CN104755936B (zh) | 选择个性化脑癌疗法的方法 | |
| Matkar et al. | Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastoma | |
| US11957677B2 (en) | Cancer treatment using FGFR inhibitors and PLK1 inhibitors | |
| US20120045523A1 (en) | Combination of a tlr3 ligand and a chemotherapy agent which acts on the intrinsic "apoptosis" pathway in the treatment of cancer | |
| JP2022529523A (ja) | 小児対象において神経膠腫を治療するためのｔｇ０２の使用 | |
| WO2025240673A1 (en) | Cancer treatment using akt inhibitors and plk1 inhibitors | |
| Mattiuzzo | Pharmacological studies of novel antitumoral compounds | |
| Bing | Characterization of AAG8 as an oncoprotein | |
| Pham | Investigation of EPO-mediated rescue from p53-dependent apoptosis in DA3-EPOR cells | |
| Loganathan | Epigenetic-Based Therapeutic Strategy for the Treatment of Ewing Sarcoma | |
| KIM | The Role of Polycomb Repressive Complex 2 and Effects of Lobarstin in Glioblastoma Multiforme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2735 DE 06-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |